lanreotide [Supplementary Concept]
somatostatin analogue that suppresses GH/IGF-I hypersecretion in acromegaly patients and used to manage neuroendocrine tumours; do not confuse with BIM 23014 C
Date introduced: August 18, 1989
MeSH Unique ID: C060347
Registry Number: 0G3DE8943Y
Heading Mapped to:
Entry Terms:
- 3-(2-naphthyl)alanyl-cystinyl-tyrosyl-tryptophyl-lysyl-valyl-cystinyl-threonine amide
- D-Nal-Cys-Tyr-Trp-Lys-Val-Cys-Thr-NH2
- angiopeptin
- naphthalenyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)threoninamide
- naphthyl-cyclo(Cys-Tyr-Trp-Lys-Val-Cys)Thr-NH2
- Nal-cyclo(Cys-Tyr-Trp-Lys-Val-Cys)-Thr-NH2
- Nal-cyclo(Cys-Tyr-Trp-Lys-Val-Cys)Thr-NH2
- 2-naphthylalanyl-cyclo(cysteinyl-tyrosyl-tryptophyl-lysyl-valyl-cysteinyl)-threoninamide
- 3-(2-naphthyl)-D-Ala-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2
- L-Threoninamide, 3-(2-naphthalenyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-, cyclic (2-7)-disulfide
- Somatuline
- DC 13-116
- DC-13-116
- DC13-116
- Somatulin
- BIM 23014
- BIM-23014
- lanreotide acetate
- Somatulina
- 188Re-lanreotide
- BIM 23014 C
- BIM-23014 C
- BIM 23014C
- lanreotide-SR
Pharmacologic Action: